TABLE 22Probability of SCD complications per 3-month cycle and cost and disutility per episode

Health stateSCD complicationProbability (%) of SCD complication by age group (years)Cost per episode (£)Disutility per episode
2–78–1819–3031+
No transfusionPain crisis5.268.7311.256.568410.02
Acute chest syndrome1.374.500.440.4418150.06
TransfusionPain crisis2.002.002.002.008410.02
Acute chest syndrome0.700.700.700.7018150.06

From: 5, Assessment of cost-effectiveness

Cover of The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation
The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.43.
Cherry MG, Greenhalgh J, Osipenko L, et al.
Southampton (UK): NIHR Journals Library; 2012 Nov.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.